Journal of Clinical Medicine Research, ISSN 1918-3003 print, 1918-3011 online, Open Access
Article copyright, the authors; Journal compilation copyright, J Clin Med Res and Elmer Press Inc
Journal website https://www.jocmr.org

Original Article

Volume 15, Number 7, July 2023, pages 377-383

Oral Semaglutide Induces Loss of Body Fat Mass Without Affecting Muscle Mass in Patients With Type 2 Diabetes

Figures

Figure 1.
Figure 1. Effect of 24-week oral semaglutide treatment on glycemic control and serum liver enzymes. Data are expressed as mean ± SE. *P < 0.05. **P < 0.01, ***P < 0.001 vs. baseline and ##P < 0.01 vs. 12 weeks. HbA1c: hemoglobin A1c; AST: aspartate aminotransferase; ALT: alanine aminotransferase; SE: standard error.
Figure 2.
Figure 2. Effect of 24-week oral semaglutide treatment on body mass index and body composition. Data are expressed as mean ± SE.**P < 0.01, ***P < 0.001 vs. baseline and #P < 0.05 vs. 12 weeks. BMI: body mass index; SMI: skeletal muscle index; SE: standard error.

Tables

Table 1. Clinical Characteristics of Participants
 
Baseline12 weeks24 weeks
Data are expressed as mean ± SE. *P < 0.05, **P < 0.01, ***P < 0.001 vs. baseline, #P < 0.05 vs. 12 weeks, ##P < 0.01 vs. 12 weeks. SBP: systolic blood pressure; DBP: diastolic blood pressure; LDL: low-density lipoprotein; HDL: high-density lipoprotein; eGFR: estimated glomerular filtration rate; SE: standard error.
Age, years54.1 ± 2.7
Height, cm165.5 ± 1.6
SBP, mm Hg140.5 ± 4.1140.8 ± 4.1137.6 ± 4.6
DBP, mm Hg81.1 ± 2.781.5 ± 2.578.9 ± 3.3
LDL-cholesterol, mg/dL132.5 ± 7.1120.6 ± 6.5**122.3 ± 7.3**
Triglyceride, mg/dL178.1 ± 14.8164.6 ± 13.3157.8 ± 15.4
HDL-cholesterol, mg/dL48.5 ± 1.845.8 ± 1.7*46.5 ± 1.7**
eGFR, mL/min/1.73 m269.2 ± 4.168.9 ± 4.164.2 ± 3.6***, ##

 

Table 2. Changes of PhA and ECW/TBW Ratio
 
Baseline12 weeks24 weeks
Data are expressed as mean ± SE. R-PhA: right phase angle; L-PhA: left phase angle; ECW/TBW: extracellular water/total body water ratio; SE: standard error.
R-PhA5.90 ± 0.165.84 ± 0.165.80 ± 0.15
L-PhA5.75 ± 0.155.68 ± 0.145.69 ± 0.14
ECW/TBW0.43 ± 0.010.44 ± 0.010.42 ± 0.02